SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: tonyt who wrote (942)11/12/1997 12:03:00 PM
From: D.Right  Read Replies (1) | Respond to of 2173
 
Dear Tony:
This is not welcome news. Although the type II trial expansion may be something they have to do, the expansion of type I is totally unexpected, at least by myself. Well, they talked to the FDA, maybe this is the FDA said what they have to do. As the two European trials will still be done by next year, I guess whatever number they get from those trials should give a reliable prediction of the final 12 months trials.
Good day.
D.Right


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News